Epidermal growth factor (EGF) is a potent mitogen that initiates signaling transduction cascades by binding to EGF receptor (EGFR) (Spaargaren et al., 1991; Carpenter and Cohen, 1990) . Following ligand binding, EGFRs oligomerize, become autophosphorylated, and finally are activated (Emlet et al., 1997) . EGFR activates two major downstream pathways: phosphatidylinositol 3-kinase (PI3K)/3-phosphoinositide-dependent protein kinase 1 (PDK-1)/Akt (also known as protein kinase B) pathway and Ras/Raf/MEK/extracellular signal-regulated kinases (ERK) signaling pathway (Carpenter and Cohen, 1990; Emlet et al., 1997; Okano et al., 2000) . PI3K/Akt pathway plays important roles in a number of cellular events like diabetes, cell proliferation, differentiation, transformation and apoptosis (Dumont et al., 1989; Lou et al., 2002) . Aberrant activation of the PI3K/Akt pathway has been widely implicated in many cancers and drugs against this pathway are likely to have broad applications for treating different types of cancer (Luo et al., 2003) .
Phospholipase A 2 (PLA 2 ) enzymes represent a family of esterases catalyzing the hydrolysis of the sn-2 position of membrane glycerophospholipids to liberate free fatty acids and lysophospholipids (Kudo and Murakami, 2002 ). There are four major families of PLA 2 s: the 14-kDa secretory PLA 2 (sPLA 2 ), the Ca 2+ -independent PLA 2 JPET#86520 5 products and PLA 2 substrate and product analogs (Hope et al., 1993) . However, many of the PLA 2 inhibitors originally thought to be selective for a specific PLA 2 are now known to have multiple other effects (Cummings et al., 2000) .
12-epi scalaradial (SLD), a natural product isolated from marine sponge (Cacospongia sp), has been shown to be a selective inhibitor of sPLA 2 (De Carvalho and Jacobs, 1991) . SLD efficiently inhibited bee venom PLA 2 (IC 50 =0.07 µM) and purified human recombinant type II sPLA 2 activity in vitro (IC 50 =5.4 µM), but displayed weak inhibition of cytosol 85 kDa-PLA 2 from U937 cells (IC 50 = 28 µM) (De Carvalho and Jacobs, 1991; Hope et al., 1993) . However, whether this compound has other effects besides inhibiting sPLA 2 activity is still unknown.
Previous studies demonstrated that SLD exerted inhibitory effect on HL-60 cell proliferation (Liu and Levy, 1997) . Recent unpublished work in our laboratory indicated that SLD also inhibited the proliferation of many other cell lines. Given EGFR/PI3K/Akt signaling pathway plays important roles in cell proliferation, we investigated the effect of SLD on EGFR-mediated signaling. Our results revealed that SLD inhibited EGFR-mediated Akt phosphorylation and this novel effect was independent of sPLA 2 . Preparation of Cell Lysates and Western Blot. After drug treatment, cells were washed twice with ice-cold PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 , pH 7.4) and total cell lysates were collected in SDS sample buffer (50 mM Tris-HCl, pH 6.8, 100 mM DTT, 2 % SDS, 0.1 % Bromophenol Blue, 10 % glycerol). Cell lysates containing equal amount of protein were separated by SDS-PAGE and transferred to polyvinylidine difluoride membranes. After being blocked in 5 % non-fat milk in TBST (Tris-buffered saline with 0.1% Tween 20, pH 7.6), membranes were incubated with the appropriate primary antibodies at 4 °C overnight and exposed to secondary antibodies for 2 h at room temperature. were mounted on slide glasses with 50 % glycerol in carbonate buffer (pH 9.0) and observed with a laser-scanning confocal microscope (Leica).
PI3K Activity Assay.
The assay was performed as described (Whitman et al., 1985) . Briefly, cells were washed twice with ice-cold PBS and lysed on ice in lysis buffer (20 mM Tris-HCl, pH 7.5, 137 mM NaCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 10 % (v/v) glycerol, 1 % Nonidet P-40, 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 50 mM sodium fluoride, 2 µM leupeptinin, 2 µM aprotinin and 1 mM phenylmethylsulfonyl fluoride). Insoluble material was removed by centrifugation at 12,000 rpm at 4 °C for 10 min. Cell lysates (500 µg) were subjected to immunoprecipitation with anti-PI3K p85 antibody for 2 h followed by the addition of 20 µl of 1:1 slurry of protein G-Sepharose beads for an additional hour at 4 °C.
The immunocomplexes were incubated with 0.1 mg/ml L-α-phosphatidylinositol, (Wu et al., 1998 Akt phosphorylation in BEL-7402 cells and this stimulation was also inhibited by SLD pretreatment (Fig. 2) . Taken together, these data indicate that the effect of SLD on EGF-stimulated Akt phosphorylation is not cell type-specific and SLD may also down-regulated other tyrosine kinase receptor-mediated signaling transduction.
Other phospholipase inhibitors did not inhibit EGF-stimulated Akt
phosphorylation. Since SLD was a well-known selective inhibitor of sPLA 2 , we next investigated whether other phospholipase inhibitors have the same inhibitory effect on
Akt phosphorylation. Among the tested inhibitors, the substrate analog thioetheramide-PC showed selectivity towards sPLA 2 and has been shown to markedly reduce the sulfite-induced generation of arachidonic acid (AA) metabolites in alveolar macrophages as well as rosiglitazone-induced prostaglandin E2 release in rat aortic vascular smooth muscle cells (Yu et al., 1990; Beck-Speier et al., 2003; Bishop-Bailey and Warner, 2003) . We incubated BEL-7402 cells with different doses of thioetheramide-PC before EGF stimulation. To our surprise, thioetheramide-PC failed to inhibit Akt phosphorylation even at dose of 30 µ M (Fig. 3A) . Arachidonyl trifluoromethyl ketone (AACOCF 3 , 10 µ M), a specific inhibitor of cPLA 2 (Street et al., 1993) , methyl arachidomyl fluorophosphonate (MAFP, 10 µ M), an inhibitor of cPLA 2 and iPLA 2 (Lio et al., 1996; Cummings et al., 2000) , and U73122 (10
This article has not been copyedited and formatted. The final version may differ from this version. inhibitor of phospholipase C (Zheng et al., 1995) , had no effect on EGF-stimulated Akt phosphorylation, either (Fig. 3 , B, C and D). In addition, indomethacin (10 µ M), an inhibitor of cyclooxygenases, which are downstream enzymes of PLA 2 and convert AA to prostaglandins (Touhey et al., 2002) , could not inhibit EGF-stimulated Akt phosphorylation (Fig. 3E) . These results indicate the inhibitory effect on EGFR-mediated Akt phosphorylation is specific for SLD.
SLD blocked EGF-induced PDK-1 membrane translocation. Akt activation requires phosphorylations at two critical residues: Thr308 at the activation loop of the catalytic domain and Ser473 at the hydrophobic C terminal domain (Alessi et al., 1996) . Upon EGF stimulation, PI3K increases the levels of phosphatidylinositol 3, 4, 5-trisphosphate (PIP 3 ), which recruits PDK-1 as well as Akt to the plasma membrane where PDK-1 phosphorylates Thr308 of Akt (Scheid et al., 2002; Stephens et al., 1998) . Previous results showed that only using pretreatment protocol was SLD able to inhibit EGF-stimulated Akt phosphorylation. So we hypothesize that SLD inhibits sPLA 2 exhibits its biological functions partially through enzymatically hydrolyzing membrane phospholipids to release AA and other lipid metabolites (Kudo and Murakami, 2002; Hanasaki and Arita, 2002) . However, our results showed AA (30 µ M) could not rescue SLD inhibition of EGF-stimulated Akt phosphorylation (Fig.   6A ), suggesting that this inhibitory effect of SLD may be independent of sPLA 2 . To confirm this hypothesis, we first used ERK1/2 as a control to determine whether AA is active or not in our system because AA has been reported to stimulate ERK1/2 phosphorylation (Dulin et al., 1998; Silfani and Freeman, 2002) . As seen from (Fig. 6C ).
These data indicate that SLD inhibits ERK1/2 phosphorylation through sPLA 2 and AA is capable of reversing the inhibitory effect of SLD on sPLA 2 -mediated biological effects, at least ERK1/2 activation. The failure of AA to reverse the inhibitory effect of SLD on Akt implies that SLD inhibition of EGF-stimulated Akt phosphorylation may be independent of sPLA 2 . 7E ). These results demonstrated that SLD inhibited ERK1/2 phosphorylation through sPLA 2 s, which was consistent with the conclusion from AA experiments.
However, overexpression of neither sPLA 2
inhibition of Akt phosphorylation (Fig. 7F ). Of note, the SLD concentration (5 µM)
used here was relative lower as compared with the concentrations used in previous experiments and 5 µM SLD only partially inhibited EGF-stimulated Akt phosphorylation (Fig. 7F) .
The percentage inhibition of EGF-stimulated Akt
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Discussion
Previous studies show that SLD is a selective inhibitor of sPLA 2 (De Carvalho and Jacobs, 1991; Hope et al., 1993; Marshall et al., 1994) . In the present study, we also showed that SLD effectively inhibited sPLA 2 activity (Fig. 7B) . The selective inhibition of sPLA 2 by SLD blocked the release of AA, the activation of inducible NO synthase and transcription factor NF-B, the production of eicosanoid, and the increase in intracellular Ca 2+ in response to stimulators in different cell types Baek et al., 2000; Thommesen et al., 1998; Barnette et al., 1994) . Besides these well known effects on phospholipid metabolism, we demonstrated here that SLD dose-and time-dependently inhibited EGF-stimulated
Akt phosphorylation in hepatocellular carcinoma BEL-7402 cells as well as in breast
cancer MDA-MB-435 cells and human endothelial cells HMEC, and more importantly, SLD inhibited PDK-1 membrane translocation and PI3K activity. Our results clearly show that inhibition of PI3K/Akt signaling is novel and may be a common pharmacological effect of SLD. This is of importance, given that the role of PI3K/Akt signaling in cellular functions. In addition, SLD also inhibited insulin-stimulated Akt phosphorylation, suggesting SLD acts on a target which is a common event in receptor tyrosine kinase-mediated signaling. However, whether the target is PI3K or the upstream kinases of PI3K remains to be further identified.
Since SLD is an effective inhibitor of sPLA 2 and EGF has been shown to stimulate PLA 2 activity (Spaargaren et al., 1992; Schalkwijk et al., 1995; Croxtall et al., 1995) , it is possible that SLD inhibition of EGFR/PI3K/Akt signaling pathway This article has not been copyedited and formatted. The final version may differ from this version. observed to abrogate the effect of SLD on Akt. Based on the facts mentioned above, we believe that SLD inhibition of EGFR-mediated Akt phosphorylation is independent of sPLA 2 .
Many PLA 2 inhibitors originally thought to be selective for a specific PLA 2 are now known to inhibit other isoforms. For example, manoalide has previously been shown to be a potent inhibitor of venom phospholipases A 2 . Now it reveals that manoalide inhibits both general PLA 2 and phosphoinositide-specific phospholipase C (Bennett et al., 1987; Cummings et al., 2000) . MAFP, the inhibitor of cPLA 2 with an IC 50 of ~0.5 µM for purified cPLA 2 , also inhibits iPLA 2 purified from murine macrophage-like P388D1 cells with IC 50 of 0.5 µM (Lio et al., 1996) . The failure of JPET#86520 22 other PLA 2 inhibitors AACOCF3 and MAFP, and phospholipase C inhibitor U73122, to inhibit EGFR-mediated Akt phosphorylation suggests it is not likely that SLD inhibited Akt phosphorylation through inhibiting other isoforms of phospholipases, at least three isoforms, cPLA 2 , iPLA 2 and phospholipase C.
In summary, this study revealed that SLD possessed a novel effect besides its inactivating sPLA 2 , i.e., SLD inhibits EGFR-mediated Akt activation. This novel effect of SLD is independent of sPLA 2 . Provided that Akt is a critical mediator in cellular biology, our findings provide important evidence for further exploring the pharmacological effects of SLD. 
